Analysts Anticipate Valeritas Holdings, Inc. (VLRX) to Announce -$1.37 EPS

Wall Street brokerages expect Valeritas Holdings, Inc. (NASDAQ:VLRX) to post ($1.37) earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have issued estimates for Valeritas Holdings’ earnings, with the lowest EPS estimate coming in at ($1.56) and the highest estimate coming in at ($1.17). Valeritas Holdings posted earnings per share of ($8.72) in the same quarter last year, which would indicate a positive year over year growth rate of 84.3%. The business is expected to issue its next earnings results on Wednesday, August 9th.

According to Zacks, analysts expect that Valeritas Holdings will report full year earnings of ($8.92) per share for the current fiscal year, with EPS estimates ranging from ($10.51) to ($7.33). For the next financial year, analysts forecast that the business will report earnings of ($4.59) per share, with EPS estimates ranging from ($5.53) to ($3.65). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Valeritas Holdings.

Valeritas Holdings (NASDAQ:VLRX) last announced its earnings results on Friday, May 12th. The company reported ($6.92) EPS for the quarter, missing the consensus estimate of ($2.72) by $4.20. The company had revenue of $4.61 million for the quarter, compared to analysts’ expectations of $4.64 million.

Several research firms have issued reports on VLRX. B. Riley reaffirmed a “buy” rating and set a $10.00 price target on shares of Valeritas Holdings in a research report on Tuesday, April 4th. Cowen and Company started coverage on shares of Valeritas Holdings in a research report on Monday, April 17th. They issued an “outperform” rating on the stock. Finally, ValuEngine lowered shares of Valeritas Holdings from a “sell” rating to a “strong sell” rating in a research report on Thursday, May 11th.

Shares of Valeritas Holdings (NASDAQ:VLRX) traded up 3.38% on Tuesday, reaching $4.90. 33,640 shares of the company traded hands. The stock’s market cap is $8.04 million. The stock has a 50 day moving average of $6.31 and a 200 day moving average of $25.25. Valeritas Holdings has a 52-week low of $4.51 and a 52-week high of $52.00.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Mideast Time and is owned by of Mideast Time. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at

In other Valeritas Holdings news, major shareholder Capital Royalty L.P. purchased 4,000,000 shares of the stock in a transaction that occurred on Tuesday, March 28th. The shares were acquired at an average cost of $10.00 per share, with a total value of $40,000,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John Edward Timberlake purchased 5,000 shares of the stock in a transaction that occurred on Wednesday, May 17th. The shares were acquired at an average cost of $5.14 per share, for a total transaction of $25,700.00. Following the completion of the transaction, the insider now owns 23,037 shares of the company’s stock, valued at approximately $118,410.18. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 4,010,400 shares of company stock worth $40,074,430.

An institutional investor recently bought a new position in Valeritas Holdings stock. HighTower Advisors LLC purchased a new position in Valeritas Holdings, Inc. (NASDAQ:VLRX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 27,400 shares of the company’s stock, valued at approximately $195,000. HighTower Advisors LLC owned 1.67% of Valeritas Holdings as of its most recent SEC filing.

Valeritas Holdings Company Profile

Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.

12 Month Chart for NASDAQ:VLRX

Get a free copy of the Zacks research report on Valeritas Holdings (VLRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2017 Mideast Time.